scholarly journals The burden of atherosclerosis in Portugal

2020 ◽  
Author(s):  
João Costa ◽  
Joana Alarcão ◽  
Francisco Araujo ◽  
Raquel Ascenção ◽  
Daniel Caldeira ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Clinical Manifestations ◽  
Premature Death ◽  
Mortality Data ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Mainland Portugal ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Years Lived With Disability

Abstract Aims This article sought to estimate the burden of disease attributable to atherosclerosis in mainland Portugal in 2016. Methods and results The burden of atherosclerosis was measured in disability-adjusted life years following the latest 2010 Global Burden of Disease (GBD) methodology. Disability-adjusted life years were estimated as the sum of years of life lost (YLL) with years lived with disability (YLD). The following clinical manifestations of atherosclerosis were included: ischaemic heart disease (IHD) (including acute myocardial infarction, stable angina, and ischaemic heart failure), ischaemic cerebrovascular disease (ICVD), and peripheral arterial disease (PAD). Years of life lost were estimated based on all-cause mortality data for the Portuguese population and mortality due to IHD, ICVD, and PAD for the year 2016 sourced from national statistics. Standard life expectancy was sourced from the GBD study. Years lived with disability corresponded to the product of the number of prevalent cases by an average disability weight for all possible combinations of disease. Prevalence data for the different clinical manifestations of atherosclerosis were sourced from epidemiological studies. Disability weights were sourced from the published literature. In 2016, 15 123 deaths were attributable to atherosclerosis, which corresponded to 14.3% of overall mortality in mainland Portugal. Disability-adjusted life years totalled 260 943, 75% due to premature death (196 438 YLL) and 25% due to disability (64 505 YLD). Conclusion Atherosclerosis entails a high disease burden to society. A large part of this burden would be avoidable if evidence-based effective and cost-effective interventions targeting known risk factors, from prevention to treatment, were implemented.

scholarly journals 1442The burden of COVID-19 in Australia in 2020

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Lynelle Moon ◽  
Anna Reynolds ◽  
Michelle Gourley
Keyword(s):  
Burden Of Disease ◽  
Disease Burden ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Australian Population ◽  
Healthy Life ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Years Lived With Disability ◽  
The Impact

Abstract Background During 2020, there were nearly 28,500 cases of COVID-19 in Australia. Burden of disease estimates for COVID-19 have not been calculated for the Australian population. Burden of disease data on COVID-19 provide valuable information on the impact of the disease, including both fatal and non-fatal effects. Methods Burden of disease is measured using the summary measure disability-adjusted life years (DALYs). One DALY is 1 year of ‘healthy life’ lost due to illness (Years Lived with Disability) and/or death (Years of Life Lost)—the more DALYs associated with a disease or injury, the greater the burden. The analysis draws on Australian deaths, incidence and severity, as well as methods and other inputs developed in other countries reflecting current understanding about this new disease. Results There were over 8,300 DALYs lost due to COVID-19 in 2020 in Australia; 97% of the disease burden arose from fatal cases. Males lost an average of 10.7 years, and females 8.1 years, due to dying from COVID-19, using an aspirational life expectancy. The burden of disease estimates for Australia for COVID-19 are much lower than the leading diseases causing burden. Conclusions The relatively low burden for COVID-19 in Australia in 2020 compared to other diseases and other countries reflects the success Australia had in containing the virus. Key messages Most of the burden due to COVID-19 in Australia was fatal. Burden of disease estimates for COVID-19 in Australia for 2020 are much lower than the leading diseases.

scholarly journals Aumento da carga de dengue no Brasil e unidades federadas, 2000 e 2015: análise do Global Burden of Disease Study 2015

2017 ◽  
Vol 20 (suppl 1) ◽  
pp. 205-216 ◽  
Author(s):  
Valdelaine Etelvina Miranda de Araújo ◽  
Juliana Maria Trindade Bezerra ◽  
Frederico Figueiredo Amâncio ◽  
Valéria Maria de Azeredo Passos ◽  
Mariângela Carneiro
Keyword(s):  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study ◽  
Years Lived With Disability

RESUMO: Objetivo: Descrever as principais métricas sobre dengue geradas pelo Global Burden of Disease (GBD) Study 2015, para o Brasil e suas 27 unidades federadas, nos anos de 2000 e 2015. Métodos: As métricas descritas foram: taxas de incidência e de mortalidade por dengue, padronizadas por idade, years of life lost (YLL), years lived with disability (YLD) e disability adjusted life years (DALY) (frequência absoluta e taxas padronizadas por idade). As métricas estimadas foram apresentadas com intervalos de incerteza (II 95%) para 2000 e 2015, acompanhadas da variação relativa percentual. Resultados: Verificou-se aumento de 232,7% no número de casos e de 639,0% no número de mortes entre os anos de 2000 e 2015 no país. A taxa de incidência variou 184,3% e a taxa de mortalidade mostrou-se baixa, mas com aumento de 500,0% no período avaliado. As taxas de YLL, YLD e DALY aumentaram 420,0, 187,2 e 266,1%, respectivamente. Em 2015, DALY foi semelhante entre mulheres e homens (21,9/100.000). O DALY aumentou mais que o dobro em todas as unidades da federação. Conclusão: O aumento acentuado de dengue ao longo dos anos associa-se à introdução e/ou circulação de um ou mais sorotipos do vírus e crescente proporção de pacientes acometidos pela forma grave da doença. Apesar da baixa taxa de mortalidade, a dengue contribui para considerável perda de anos saudáveis de vida no Brasil por acometer elevado número de pessoas, de todas as faixas etárias, ocasionando algum grau de incapacidade durante a infecção sintomática, e em razão dos óbitos, principalmente, em crianças.

scholarly journals Measuring the Burden of Disease Due to Preterm Birth Complications in Korea Using Disability-Adjusted Life Years (DALY)

2019 ◽  
Vol 16 (3) ◽  
pp. 519 ◽  
Author(s):  
Hyun Kim ◽  
Min-Woo Jo ◽  
Seok-Hwan Bae ◽  
Seok-Jun Yoon ◽  
Jin Lee
Keyword(s):  
Preterm Birth ◽  
Burden Of Disease ◽  
Premature Birth ◽  
Disability Weight ◽  
Mortality Data ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Birth Complications ◽  
Disability Adjusted Life ◽  
Life Years

The premature birth rate in Korea has increased from 13.5% in 2008 to 15.7% in 2013. The complications of premature birth are a major determinant of neonatal mortality and morbidities. The purpose of this study was to estimate the burden of premature birth in Korea using disability-adjusted life years (DALY). DALY consists of years of life lost (YLL) and years lost due to disability (YLD). In this study, preterm birth complications refer to nine diseases: P07, P22, P25, P26, P27, P28, P52, P77, P612, and H351 (International Classification of Diseases—10th Revision). YLL was calculated using mortality data from the 2012 National Health Insurance Data. YLD is a function of the prevalence, disability weight (DW), and duration of each complication. DW was determined by the Korean Disability Weight Study for National Burden of Disease in Korea 2013/2015. The burden of premature birth in Korea is 79,574 DALY (YLL: 43,725; YLD: 35,849). The burden for men (DALY: 43,603; YLL: 24,004; YLD: 19,599) is higher than that of women (DALY: 35,970; YLL: 19,720; YLD: 16,250). This study could provide essential data for evaluating the effects of policies intended to reduce preterm birth.

scholarly journals Estimation of Burden of Cystic Echinococcosis in Iran Using Disability Adjusted Life Years (DALYs) in 2018

2021 ◽  
Author(s):  
Fateme Parandin ◽  
Fatemeh Heydarpour ◽  
Mehdi Mohebali ◽  
Ahmad Ali Hanafi-Bojd ◽  
Ali Akbari Sari ◽  
...  
Keyword(s):  
Premature Death ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Public Concern ◽  
Policy Makers ◽  
Control Programs ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Standard Life ◽  
And Control

Background: Human hydatidosis as a public concern has increased in a number of countries that have reduced control programs for the disease due to lack of resources or policies. We aimed to estimate Disability-Adjusted Life Years (DALYs) for human hydatidosis in Iran in 2018. Methods: Data were collected from the Center of Communicable Diseases Control, Ministry of Health &Medical Education, Tehran, Iran in 2018. To calculate DALYs, years of life lost due to premature death (YLL) with years of life with disability (YLD) were calculated according to the formula as DALY = YLL + YLD. The standard life expectancy lost method (SEYLL) was used to calculate the years lost due to premature death. Results: DALYs for human hydatidosis was calculated as 1210.12 years (YLD equals to 177.12 and YLL equals to 1033) in Iran for the year 2018. It was estimated to be 700.2 years for men and 509.8 years for women.  DALYs in men were significantly different from women (P= 0.001) so DALYs were more in men than women were. YLD was calculated at 78.228 years in men and 98.892 years in women and in both men and women at 177.12 years. YLD was significantly different in women compared to men (P=0.001), so YLD in women was more than in men. Conclusion: We reached considerable indices for hydatidosis in our study. Therefore, disease prevention and control programs in Iran seem necessary by the policy makers.

Life Years at Stake

2019 ◽  
pp. 48-60
Author(s):  
Andreas Mogensen
Keyword(s):  
Life Expectancy ◽  
Global Health ◽  
Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Disability Adjusted Life Years ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Ethical Basis

In quantifying the global burden of disease in terms of Disability-Adjusted Life Years (DALYs), we must determine both Years of Life Lost (YLLs) and Years Lost to Disability (YLDs). In setting priorities for global health, many have felt that YLLs should not always simply equal life expectancy at death. To this end, Dean Jamison and colleagues recommend the use of a DALY metric that incorporates Acquisition of Life Potential (ALP). When an individual dies, the YLLs that we would otherwise count are multiplied by the value of the ALP function, which rises gradually from 0 to 1 during the first stages of an individual’s life. Jamison et al. do not provide a detailed philosophical justification for the use of gradual ALP. In this chapter I explain why I believe the Time-Relative Interest Account represents the most plausible ethical basis for the ALP approach and describe how we might model ALP in light of this account.

Sign in / Sign up

Export Citation Format

Share Document